Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer

Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer ( Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020

Latest updates to the ESMO bone health guidelines

Prof Robert Coleman - University of Sheffield, Sheffield, UK
Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )
22 Sep 2020

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection

Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
22 Sep 2020

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers

Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers ( Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany )
22 Sep 2020

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
22 Sep 2020

Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC

Dr Alex Spira and Dr Joshua Sabari
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )
21 Sep 2020

Impact of COVID-19 pandemic on cancer care: A global collaborative study

Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia
Impact of COVID-19 pandemic on cancer care: A global collaborative study ( Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia )
21 Sep 2020

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
20 Sep 2020

The emerging importance of studying immune regulatory molecule expression patterns

Dr Jacob Adashek - The University of South Florida, Tampa, USA
The emerging importance of studying immune regulatory molecule expression patterns ( Dr Jacob Adashek - The University of South Florida, Tampa, USA )
19 Sep 2020

OncoAlert and ecancer weekly roundup for September 6-13, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for September 6-13, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
14 Sep 2020

Future directions of PARP inhibitors in prostate cancer

Dr Jacob Adashek - The University of South Florida, Tampa, USA
Future directions of PARP inhibitors in prostate cancer ( Dr Jacob Adashek - The University of South Florida, Tampa, USA )
10 Sep 2020

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation